Trial Profile

C-TIL051 in Anti-PD1 Resistant Metastatic Non-Small Cell Lung Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avipendekin pegol (Primary) ; C TIL051 (Primary) ; Interleukin-2 (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer
Focus Adverse reactions
Sponsors AbelZeta Pharma; Cellular Biomedicine Group

Most Recent Events

16 Feb 2024 Planned initiation date changed from 1 Dec 2023 to 12 Feb 2024.
20 Nov 2023 According to a Cellular Biomedicine Group media release, the Cellular Biomedicine Group has changed its name to has changed its name to AbelZeta Pharma, Inc. (AbelZeta), after spin-off of the Company's stem cell business division. AbelZeta to focus greater resources on the development of immune cell therapy for cancer and Inflammation & Immunology (I&I) diseases.
13 Nov 2023 Planned End Date changed from 1 Mar 2027 to 1 Aug 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com